Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
25%(2 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
2
18%
Ph phase_4
3
27%
Ph phase_1
1
9%
Ph phase_3
2
18%
Ph phase_2
2
18%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
3(30.0%)
N/ANon-phased studies
2(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(8)
Terminated(2)
Other(1)

Detailed Status

Completed8
Terminated1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 32 (20.0%)
Phase 43 (30.0%)
N/A2 (20.0%)

Trials by Status

terminated19%
completed873%
unknown19%
withdrawn19%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11